stockrowPharvaris N.V.
PHVS Healthcare Biotechnology
- EPS
- +13.8%
- Free cash flow
- −17.3%
- Total debt
- +4.31%
Quarter to June 2026, against a year earlier
Follow PHVS
Alert me
Pharvaris N.V. (PHVS) Return on assets
Pharvaris N.V.'s return on assets over the twelve months to 30 June 2026 was −64.4%, down 3.9 percentage points from fiscal 2025 (−60.6%). Over the past ten years it has ranged from −163.9% (fiscal 2018) to −27.6% (fiscal 2021); the current reading is higher than 38% of that period. That is below the Biotechnology industry median of −45.6% and below the Healthcare sector median of −29.3%.
Return on assets, annual
Embed this chart
Annual newest first
| Period | Return on assets | Change (points) |
|---|---|---|
| FY2025 | −60.6% | (21.67) |
| FY2024 | −38.9% | (3.00) |
| FY2023 | −35.9% | 1.71 |
| FY2022 | −37.6% | (10.02) |
| FY2021 | −27.6% | 15.24 |
| FY2020 | −42.8% | 18.43 |
| FY2019 | −61.3% | 102.59 |
| FY2018 | −163.9% | — |
Against its own ten years
Return on assets against peers
| Company | Return on assets |
|---|---|
| ADMA ADMA Biologics Inc compare | 28.0% |
| VCEL Vericel Corporation compare | 6.86% |
| NAMS NewAmsterdam Pharma Company N.V. compare | −27.8% |
| RXRX Recursion Pharmaceuticals, Inc. compare | −36.3% |
| PVLA Palvella Therapeutics, Inc. compare | −37.7% |
| CLDX Celldex Therapeutics, Inc. compare | −40.8% |
| IMNM Immunome, Inc. compare | −59.0% |
| PHVS Pharvaris N.V. | −64.4% |
| BHVN Biohaven Ltd. compare | −161.3% |
| Biotechnology industry median | −45.6% |
| Healthcare sector median | −29.3% |
| Market median | 0.00% |
What Return on assets is
ROA tells an investor how much profit a company earns for shareholders from the assets it uses to run its business.
Annual: Net Income Allotted to Shareholders ÷ Average Assets; TTM: Net Income Allotted to Shareholders ÷ Average Assets (latest quarter)